• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Ispire Technology Advances Vapor Safety and Compliance With First-Ever FDA PMTA Filing for Blockchain-Powered Age-Gating System

    5/1/25 8:30:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $ISPR alert in real time by email

    Ispire's Strategic Investment in IKE Tech Positions Company at Forefront of Vapor Innovation, Youth Prevention and Regulatory Readiness

    LOS ANGELES, May 1, 2025 /PRNewswire/ --  Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a trailblazer in vaping technology and precision dosing, announced that IKE Tech LLC ("IKE Tech"), a joint venture that includes Ispire as a founding partner, has filed a component Pre-Market Tobacco Product Application (PMTA) and Tobacco Product Master File (TPMF) with the U.S. Food and Drug Administration (FDA) for its Bluetooth Low Energy (BLE) System-on-a-Chip.

    This filing marks a historic first: a complete PMTA submission for a standalone, interoperable, blockchain-enabled age-verification component, designed for universal integration across all Electronic Nicotine Delivery Systems (ENDS) devices. Unlike traditional systems that verify age once at purchase, IKE's platform requires continuous, real-time verification for device access, providing an unprecedented level of security against underage vaping. IKE formally requested an expedited review of the application, citing the system's potential to enhance public health.

    "Ispire will benefit not only from commercial sales of the component but also from the rights to integrate the technology into our own devices—positioning us to lead in regulatory-compliant innovation and unlock new revenue opportunities," said Michael Wang, co-CEO of Ispire. "This submission marks a defining moment for both the vaping industry and our mission to lead through innovation. By paving the way for FDA-authorized, interoperable age-gating technology, we're helping to redefine vapor safety, open new global regulatory pathways and create economic value for Ispire and the broader ENDS market."

    The IKE BLE chip, powered by blockchain technology, is a secure, interoperable, point-of-use identity and age-verification system designed to prevent unauthorized use of ENDS devices. In a multi-center Human Factors Validation Study submitted with the PMTA, the technology achieved:

    • 100% effectiveness in preventing device activation by underage users,
    • 100% accuracy in demographic verification,
    • User error rates below 1%, underscoring ease of use for adults,
    • 91% user satisfaction with app simplicity and functionality.   

    "We're not just building tech—we're building trust," said John Patterson, president of IKE Tech. "Our goal is to create an interoperable, FDA-authorized standard that puts youth safety first while ensuring adults retain access to reduced-risk alternatives."

    The PMTA filing includes plans to publish clinical protocols for peer review, reinforcing Ispire's commitment to transparency and scientific rigor. By setting a new standard for youth prevention and device security, this technology has the potential to serve as a key enabler for expanded regulatory pathways for flavored vaping products—critical to offering adult smokers more choices while maintaining youth protections.

    "With this submission, Ispire and IKE Tech are building a smarter, better vaping future," added Wang. "We are proud to be part of a solution that meets the highest public health standards while opening global regulatory and commercial opportunities for our partners, customers and shareholders."

    The submission builds on a successful pre-PMTA meeting with the FDA in Q4 2024, during which regulators confirmed their willingness to evaluate component-based PMTAs and encouraged cross-center guidance, particularly in software and data privacy areas.

    About IKE Tech LLC

    IKE Tech LLC is a joint venture comprised of three leading technology and research companies -- Ispire Technology Inc, Touch Point Worldwide Inc. d/b/a Berify, and Chemular Inc. -- dedicated to revolutionizing Identity and Age Verification (IAV) technology solutions. Recognizing the absence of a universal point-of-sale IAV solution and recognition of the need for one, these companies joined forces to create a unique IAV technology component. IKE's mission is to set the gold standard for IAV by (i) permitting access to electronic nicotine delivery systems by authorized adult users while (ii) preventing underage access through a "plug and play" component compatible across different devices and platforms. 

    About Ispire Technology Inc.

    Ispire is engaged in the research and development, design, commercialization, sales, marketing and distribution of branded e-cigarettes and cannabis vaping products. The Company's operating subsidiaries own or license more than 400 patents worldwide. Ispire's branded e-cigarette products are marketed under the Aspire name and are sold worldwide (except in the U.S., People's Republic of China and Russia) primarily through its global distribution network. The Company also engages in original design manufacture (ODM) relationships with e-cigarette brands and retailers worldwide. The Company's cannabis products are marketed under the Ispire brand name primarily on an ODM basis to other cannabis vapor companies. Ispire sells its cannabis vaping hardware in the US, Europe and South Africa and it recently commenced marketing activities and customer engagement in Canada and Latin America. For more information, visit www.ispiretechnology.com or follow Ispire on Instagram, LinkedIn, Twitter and YouTube.

    Forward Looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended ("Securities Act") as well as Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended, that are intended to be covered by the safe harbor created by those sections. Forward-looking statements, which are based on certain assumptions and describe the Company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate," "strategy," "future," "likely" or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the Company's strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the Company's actual results and financial condition to differ materially from those indicated in the forward-looking statements. Such forward-looking statements include, but are not limited to, risks and uncertainties including those regarding: the Company's ability to collect its accounts receivable in a timely manner, the Company's business strategies, the ability of the Company to market to the Ispire ONE™, Ispire ONE's success if meeting its goals, the ability of its customers to derive the anticipated benefits of the Ispire ONE™ and the success of their products on the markets; the Ispire ONE™ proving to be safe, and the risk and uncertainties described in "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations," "Cautionary Note on Forward-Looking Statements" and the additional risk described in Ispire's Annual Report on Form 10-K for the year ended June 30, 2023 and any subsequent filings which Ispire makes with the U.S. Securities and Exchange Commission. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in the press release relate only to events or information as of the date on which the statements are made in the press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events except as required by law. You should read this press release with the understanding that our actual future results may be materially different from what we expect.

    IR Contacts:

    For more information, kindly contact:

    Investor Relations

    Sherry Zheng

    718.213.7386

    [email protected]

    KCSA Strategic Communications

    Phil Carlson

    212.896.1233

    [email protected]

    PR Contact:

    Ellen Mellody

    570.209.2947

    [email protected]

     

    Cision View original content:https://www.prnewswire.com/news-releases/ispire-technology-advances-vapor-safety-and-compliance-with-first-ever-fda-pmta-filing-for-blockchain-powered-age-gating-system-302443512.html

    SOURCE Ispire Technology Inc.

    Get the next $ISPR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ISPR

    DatePrice TargetRatingAnalyst
    5/20/2024$11.00Buy
    ROTH MKM
    More analyst ratings

    $ISPR
    Leadership Updates

    Live Leadership Updates

    See more
    • Ispire Technology Inc. Announces Appointment of Jay Yu as Chief Financial Officer

      Jie "Jay" Yu has a strong track record of excellence in public company accounting, and has served in the role of Vice President of Finance for Ispire since June 2023 Ispire also further streamlines operations by cutting an estimated $3.6 million in annual payroll in May 2025 Ispire expects to also cut up to an additional $6.6 million in annual operating expenses over the next three months, for a total estimated annualized expense reduction of $10.2 million LOS ANGELES, May 15, 2025 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today announced the appointment of Jie "Jay" Yu as the

      5/15/25 4:30:00 PM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Ispire Technology Inc. Announces Key Leadership Appointments

      LOS ANGELES, Aug. 14, 2023 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or "the Company") (NASDAQ:ISPR), a leader in vapor technology, providing high-quality, innovative products with first-class performance, announced today the appointment of Michael Wang as its Co-Chief Executive Officer.  Mr. Wang previously served as Chief Financial Officer. Concurrently, Daniel J. Machock was appointed as the new Chief Financial Officer. Mr. Wang has assumed the role of Co-Chief Executive Officer alongside Tuanfang Liu, as Co-Chief Executive Officer. This strengthened leadership structure is designed to refine Ispire's strategic direction and spearhead the Company's future growth. Ispire's decision

      8/14/23 8:35:00 AM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care

    $ISPR
    SEC Filings

    See more
    • Ispire Technology Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Ispire Technology Inc. (0001948455) (Filer)

      5/23/25 4:30:34 PM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Ispire Technology Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Ispire Technology Inc. (0001948455) (Filer)

      5/15/25 4:30:11 PM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Ispire Technology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Ispire Technology Inc. (0001948455) (Filer)

      5/12/25 7:00:13 AM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care

    $ISPR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ispire Technology Inc. Announces Approval of Interim License for Manufacturing of Nicotine Products in Malaysia

      Interim License Approved in May, with Authority to Begin Manufacturing of Nicotine Products in Malaysia Immediately LOS ANGELES, May 22, 2025 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today announced it has received the interim license from the Malaysian Government for the manufacturing of nicotine products. This is the first and only nicotine manufacturing license issued in Malaysia approved by both the Federal and State authorities and cements Ispire's position as the only company with full authorization for export, import, and production. The approval of the interim license

      5/22/25 9:00:00 AM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Ispire Technology Inc. Announces Appointment of Jay Yu as Chief Financial Officer

      Jie "Jay" Yu has a strong track record of excellence in public company accounting, and has served in the role of Vice President of Finance for Ispire since June 2023 Ispire also further streamlines operations by cutting an estimated $3.6 million in annual payroll in May 2025 Ispire expects to also cut up to an additional $6.6 million in annual operating expenses over the next three months, for a total estimated annualized expense reduction of $10.2 million LOS ANGELES, May 15, 2025 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today announced the appointment of Jie "Jay" Yu as the

      5/15/25 4:30:00 PM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Ispire Technology Inc. Reports Financial Results for Fiscal Third Quarter 2025

      Accounts Receivable Decreased from $67.7M to $60.4M Improving Company Financial PositionPost-Quarter End, IKE Tech Filed PMTA with the FDA for its Age-Gating Joint Venture Component with IKELaunched SproutTM in Collaboration with Raw Garden, an Advanced All-In-One Cannabis Vapor Device Ensuring Purity and Safety  LOS ANGELES, May 12, 2025 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported financial results for the third quarter of fiscal 2025, for the three months ending March 31, 2025. Fiscal Third Quarter 2025 Financial Results Revenue of $26.2 million versus $30.0 mil

      5/12/25 7:00:00 AM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care

    $ISPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CLO and Secretary Pryzbyla Steven P. sold $1,785 worth of shares (500 units at $3.57), decreasing direct ownership by 0.12% to 416,710 units (SEC Form 4)

      4 - Ispire Technology Inc. (0001948455) (Issuer)

      3/19/25 4:30:15 PM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care
    • CLO and Secretary Pryzbyla Steven P. sold $24,982 worth of shares (6,200 units at $4.03), decreasing direct ownership by 1% to 417,210 units (SEC Form 4)

      4 - Ispire Technology Inc. (0001948455) (Issuer)

      3/14/25 4:30:05 PM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Cox Brent was granted 8,077 shares, increasing direct ownership by 63% to 20,998 units (SEC Form 4)

      4 - Ispire Technology Inc. (0001948455) (Issuer)

      1/10/25 6:05:19 AM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care

    $ISPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ROTH MKM initiated coverage on Ispire Technology with a new price target

      ROTH MKM initiated coverage of Ispire Technology with a rating of Buy and set a new price target of $11.00

      5/20/24 7:18:59 AM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care

    $ISPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Ispire Technology Inc.

      SC 13G - Ispire Technology Inc. (0001948455) (Subject)

      7/12/24 5:00:02 PM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care

    $ISPR
    Financials

    Live finance-specific insights

    See more
    • Ispire Technology Inc. Reports Financial Results for Fiscal Third Quarter 2025

      Accounts Receivable Decreased from $67.7M to $60.4M Improving Company Financial PositionPost-Quarter End, IKE Tech Filed PMTA with the FDA for its Age-Gating Joint Venture Component with IKELaunched SproutTM in Collaboration with Raw Garden, an Advanced All-In-One Cannabis Vapor Device Ensuring Purity and Safety  LOS ANGELES, May 12, 2025 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported financial results for the third quarter of fiscal 2025, for the three months ending March 31, 2025. Fiscal Third Quarter 2025 Financial Results Revenue of $26.2 million versus $30.0 mil

      5/12/25 7:00:00 AM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Ispire Technologies Inc. Schedules Fiscal Third Quarter 2025 Earnings Conference Call

      LOS ANGELAS, May 7, 2025 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a trailblazer in vaping technology and precision dosing, announced today that it will host its earnings conference call at 8:00am ET on Monday, May 12, 2025, to discuss the Company's financial results for the fiscal third quarter ended March 31, 2025. To listen to the conference call, please dial in using the information below. When prompted upon dialing-in, please ask for the "Ispire Technology Call." Date: Monday, May 12, 2025Time: 8:00am ETDial-In Numbers: North America 888-880-3330 or International +1 646-357-8766This conference call will be webcast live and can be accessed by all

      5/7/25 4:30:00 PM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Ispire Technology Inc. to Participate in Webull Corporate Webinar Series on February 18, 2025

      LOS ANGELES, Feb. 12, 2025 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today announced that Michael Wang, Co-Chief Executive Officer, will present at the Webull Consumer Webinar Series: Consumer, on February 18, 2025. Conference Details: Webull Corporate Webinar Series - ConsumerDate/Time: Tuesday, February 18th at approximately 3:00 p.m. ETPresenter: Michael Wang, Co-CEORegistration Link: HERERecent Highlights: 2/10/25: Ispire Technology Inc. Reports Financial Results for Fiscal Second Quarter 2025 1/22/25: Ispire Technology Inc. Announces Stock Repurchase Program 1/15/25: Ispi

      2/12/25 8:00:00 AM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care